NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Arcellx Inc (ACLX) Stock Analysis

Arcellx Inc (ACLX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ACLX

$115.07

$0.00 (0.00%)

Last trade May 15, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACLX with… →

ACLX Key Statistics

As of May 15, 2026
Trading
Open
$115.03
Previous Close
$115.07
52-Week Range
50.85–115.13
Volume
13.19M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.25
Valuation
Market Cap
$6.73B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
302.09
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.07
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
+96.87%
Dividend and dates
Avg Volume
1.45M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ACLX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+76.49%
2025−14.98%
2024 (partial year)+1.97%

As of May 15, 2026.

ACLX Valuation vs Biotechnology Median

Median of 656 stocks
MetricACLXBiotechnology medianvs median
P/S ratio302.0915.2619.8x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Arcellx Inc (ACLX) carries a market capitalisation of $6.73B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 209 employees.

ACLX last closed at $115.07 on May 15, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $50.85 to $115.13. The latest close sits 126.29% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $22.29M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −4.07.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 302.09. On price-to-sales that is 19.8 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 0.25. Annualized volatility over the trailing 1 year is 88.12%. The trailing one-year price return is +96.87%.

Growth & Income

No dividend is on file for ACLX.

2026 is still running; the price is +76.49% year to date. The record holds one complete calendar year, 2025, which returned −14.98%.

Peer Comparison

Arcellx Inc (ACLX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Arcellx Inc ACLX $6.73B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Arcellx Inc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of May 15, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Arcellx Inc

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. As of April 28, 2026, Arcellx, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Visit website →